Gut bacterial metabolism of the side-chain of corticosteroids

NIH RePORTER · NIH · R01 · $352,234 · view on reporter.nih.gov ↗

Abstract

The metabolism of corticosteroids by host-associated microbiomes rivals that of host peripheral tissues. Side-chain metabolism of corticosteroids is capable of changing the functional class of steroid. The focus of the current project is elucidating the microbial enzymes involved in (Aim 1) the side-chain cleavage of cortisol and reduction of 17-keto resulting in 11-oxy-androgens (Aim 2) 16-dehydroxylation yielding 17-epiprogesterone derivatives. These pathways are significant because they are hypothesized to potentiate diseases relevant to the mission of NIH. The formation of 11-oxy-androgens in the intestine and urinary tract is hypothesized to affect host immune function, and may be a risk factor for prostate cancer. The formation of 17-epiprogesterone derivatives are known to derive from microbial metabolism of host 16-hydroxyprogesterone; however, the physiological role of these absorbed metabolites is not currently known. We have discovered enzymes involved in 17-keto steroid metabolism, and are now focusing on functional metagenomic discovery of additional isoforms (Aim 1). We also show a cultured anaerobe capable of corticosteroid 16-dehydroxylation We will apply previously established bioinformatics approaches to uncover the diversity of host-associated bacteria encoding homologous sterolbiome enzymes (phylogenetic analysis, sequence similarity networks). We present additional robust preliminary data demonstrating the feasibility of our studies that include (1) collection of 180 stool samples for functional metagenomic screening (2) utilization of RNA-Seq for steroid-inducible gene discovery (3) heterologous expression and characterization of numerous microbial sterolbiome enzymes (3) establishment of enzyme assays and steroid metabolomics. The research proposed in this application is innovative, in our opinion, because it represents a new and substantive departure from the status quo established four decades ago by combining transcriptomics, heterologous protein expression, enzyme assays, phylogenetic and sequence similarity networks, synthetic biology, and functional metagenomic screening to discover the precise nucleic acid sequences encoding corticosteroid side-chain metabolizing enzymes. Successful completion will potentiate research into the cause and effect relationships between the gut sterolbiome and host diseases, and is expected to lead to translational approaches (probiotics, enzyme inhibitors) to modulate the gut microbiome to restore and maintain health.

Key facts

NIH application ID
10913499
Project number
5R01GM145920-03
Recipient
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
Principal Investigator
Jason Michael Ridlon
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$352,234
Award type
5
Project period
2022-09-15 → 2026-07-31